Galvus 50 - Tablet Vildagliptin - 50mg 14 Tablet(s) / Strip Nevian Lifescience PLC Introduction: Galvus 50 is a medicine used to treat type 2 diabetes mellitus. It is used together with a healthy diet and regular exercise to control blood sugar levels. This helps to prevent serious complications of diabetes like kidney damage and blindness. Galvus 50 is normally prescribed when diet and exercise alone or other medicines do not prove sufficient to control your blood sugar level. Your doctor may prescribe it alone or along with other diabetes medicines. It can be taken with or without food. The dose will depend on your condition and blood sugar levels. Therefore, you should use it... Uses of Galvus 50: Type 2 diabetes mellitus Side effects of Galvus 50: HeadacheCommon coldCoughConstipationDizzinessSweatingHypoglycaemia (low blood sugar level) in combination with insulin or sulphonylurea How to use Galvus 50: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Galvus 50 may be taken with or without food, but it is better to take it at a fixed time. How Galvus 50 works: Galvus 50 is an antidiabetic medication. It works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces the fasting and postmeal sugar levels. What if you forget to take Galvus 50?: If you miss a dose of Galvus 50, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose. Indication: Type 2 DM Administration: May be taken with or without food. Adult Dose: Oral Type 2 diabetes mellitus Adult: 50 mg bid. Not recommended to use >100 mg/day. W/ metformin or a thiazolidinedione: 50 mg twice daily; w/ a sulfonylurea: 50 mg/day in the morning. Renal Dose: Renal impairment: Moderate, severe and ESRD: 50 mg once daily. Contraindication: Hypersensitivity to vildagliptin Mode of Action: Vildagliptin is a dipeptidylpeptidase-4 (DPP-4) inhibitor that improves glycaemic control by preventing DPP-4 from inactivating the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thus prolonging incretin activity in response to ingestion of nutrients. This increases insulin sensitivity, decreases glucagon secretion and improves ?-cell function. Precaution: Patient w/ cardiac failure (NYHA functional class IV), type 1 DM; history of acute pancreatitis. Not intended for the treatment of diabetic ketoacidosis. Hepatic impairment, including patients w/ pre-treatment ALT or AST >3 times the upper limit of normal (ULN). Moderate or severe renal impairment, ESRD. Monitoring Parameters Monitor liver function. Side Effect: Nausea, peripheral oedema, headache, tremor, asthenia, dizziness, constipation, hypoglycaemia, arthralgia, hepatic dysfunction, nasopharyngitis, upper resp tract infection, pancreatitis, exfoliative and bullous skin reactions. Interaction: Decreased hypoglycaemic effect w/ thiazides, corticosteroids, thyroid products and sympathomimetics.